MLICM
MRTX

Metropolitan Life Insurance Company (MetLife)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,461
Closed -$361K – 2753
2021
Q4 		$361K Buy
2,461
+137
+6% +$21.3K ﹤0.01% 1625
2021
Q3 		$411K Sell
2,324
-77
-3% -$12.4K 0.01% 1581
2021
Q2 		$388K Sell
2,401
-8,946
-79% -$1.44M 0.01% 1689
2021
Q1 		$1.94M Sell
11,347
-469
-4% -$92.9K 0.03% 528
2020
Q4 		$2.6M Buy
11,816
+1,089
+10% +$235K 0.04% 377
2020
Q3 		$1.78M Sell
10,727
-443
-4% -$60.6K 0.03% 459
2020
Q2 		$1.28M Buy
11,170
+2,222
+25% +$215K 0.02% 600
2020
Q1 		$688K Buy
8,948
+421
+5% +$37.8K 0.01% 872
2019
Q4 		$1.1M Sell
8,527
-179
-2% -$17.3K 0.02% 839
2019
Q3 		$678K Buy
8,706
+1,517
+21% +$142K 0.01% 1100
2019
Q2 		$740K Buy
7,189
+319
+5% +$24.8K 0.01% 1071
2019
Q1 		$504K Buy
6,870
+419
+6% +$28.5K 0.01% 1295
2018
Q4 		$274K Buy
6,451
+382
+6% +$15.2K 0.01% 1607
2018
Q3 		$286K Hold
6,069
– – ﹤0.01% 1744
2018
Q2 		$299K Buy
+6,069
New +$229K ﹤0.01% 1663
2016
Q2 		– Sell
-10,368
Closed -$222K – 2696
2016
Q1 		$222K Hold
10,368
– – ﹤0.01% 2110
2015
Q4 		$328K Buy
10,368
+2,664
+35% +$94.1K ﹤0.01% 1904
2015
Q3 		$265K Hold
7,704
– – ﹤0.01% 2080
2015
Q2 		$242K Buy
7,704
+366
+5% +$10.8K ﹤0.01% 2268
2015
Q1 		$215K Buy
+7,338
New +$172K ﹤0.01% 2029

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MRTX Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 2,461 shares — an estimated $361K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MRTX in Q1 2015 and held it in 20 quarters. The position peaked at $2.6M in Q4 2020. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,461 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $361K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Mirati Therapeutics, Inc. Common Stock position peaked at $2.6M in Q4 2020.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.